(Google Translate)

Products: Pfizer Inc. (PFE)

Other Pharma & Consumer(Other Pharma & Consumer)
Oncology Drugs(Oncology Drugs)
Anti-Infective Drugs(Anti-Infective Drugs)
Cardiovascular Drugs(Cardiovascular Drugs)
Musculoskeletal Drugs(Musculoskeletal Drugs)
Neuroscience Drugs(Neuroscience Drugs)
Immunology Drugs(Immunology Drugs)
Alimentary & Metabolism Drugs(Alimentary & Metabolism Drugs)

Other Pharma & Consumer

What is being offered?

This division includes legacy pharma drugs which are not reported separately, growth drugs which do not have sufficient revenues yet to be reported separately, consumer healthcare business, sterile injectables, biosimilars, infusion systems and revenue from alliances.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

All pharmaceutical companies including branded & generic manufacturers

What buyers care about?

  1. Price of drugs
  2. Side effects
  3. Subsidies available in the form of reimbursements
  4. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Other Pharma & Consumer Revenue

This includes revenues from Pfizer's alliances with other companies, legacy pharma products, sterile injectibles, biosimilars, consumer healthcare, infusion systems and other drugs not reported separately. In addition, this division also includes Xalatan as it serves a therapeutic area which is not covered by any therapeutic areas that we break down separately for modelling purpose.

Pfizer's Other Pharma & Consumer Revenue declined from nearly $27.3 billion in 2010 to $13.55 billion in 2014 primarily due to divestment of business including nutritional busines, capsugel, animal health and others, as well as generic competition for legacy products. However, the figure increased to $19.2 billion by 2017 reflecting consolidation of Hospira which Pfizer acquired in late 2015.

Chart: Pfizer's Other Pharma & Consumer Revenue

Oncology Drugs

What is being offered?

Oncology is a branch of medicine that deals with tumors. It is concerned with the diagnosis, therapy (surgery, chemotherapy, radiotherapy and other modalities), palliative care of patients with terminal cancers, screening efforts of populations (for hereditary cancers like breast cancer) and follow-up care for successful cancer treatments.

Roche, a Swiss global healthcare company along with its American subsidiary Genetech, is the biggest player in this therapeutic class. It owns some of the top selling brands including Avastin, Rituxan and Herceptin.

Pfizer has a small presence in the oncology space with drugs such as Sutent, Xalkori, Inlyta and Ibrance.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Roche, Novartis, Merck, Lilly and Takeda

What buyers care about?

  1. Price is the single biggest factor as some cancer treatment prescriptions cost upwards of $50,000 per year
  2. Subsidies available in the form of Medicare & Medicaid reimbursements
  3. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Relentless focus on R&D
  3. Strong tie-ups with distribution channels

Pfizer's Oncology Drugs Revenue

This includes revenue from Pfizer’s drugs within the oncology (cancer) therapeutic class. More specifically, this is a sum of revenues from Sutent, Xalkori, Inlyta and Ibrance. In addition, we also include probability-adjusted future revenues from oncology drugs in Pfizer's phase 3 pipeline.

Pfizer's Oncology Drugs Revenue have increased consistently over the past few years amounting to $5.2 billion in 2017.

Chart: Pfizer's Oncology Drugs Revenue

Anti-Infective Drugs

What is being offered?

Anti-Infectives are substances that counteract infection, include antiseptics, disinfectants, antibiotics, antifungal and virucidal agents.

We considered Anti-virals, Cephalosporins (Anti-Bacterial) and vaccines to be a part of this segment for the purpose of this report.

Pfizer has astrong position in this segment. Well known brands include Zithromax, Zyvox, Diflucan, Vfend and the Prevnar franchise of vaccines.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Gilead, Glaxo SmithKline, Bristol Myers-Squibb, Roche, Novartis, Astra Zeneca, Johnson & Johnson, Merck, Sanofi-Aventis and Abbott Labs.

What buyers care about?

  1. Price of drugs
  2. Subsidies available in the form of reimbursements
  3. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Anti-Infective Drugs Revenue

This includes revenue from Pfizer’s drugs within the anti-infective therapeutic class, including vaccines. More specifically, this is a sum of revenues from Prevnar, Zyvox, Vfend, Zithromax/Zmax, Tygacil, Diflucan, FSME-IMMUN/TicoVac, Unasyn and Sulperazon. In addition, we also include probability-adjusted future revenues from anti-infective drugs in Pfizer's phase 3 pipeline.

Pfizer's Anti-Infective Drugs Revenue has increased sharply between 2013 and 2015 due to exceptional growth in Prevnar vaccine. However, the figure fell in 2016 to $7.9 billion and $7.4 billion in 2017, as the vaccination rates among adults fell in the U.S. and Zyvox lost its patent.

Chart: Pfizer's Anti-Infective Drugs Revenue

Cardiovascular Drugs

What is being offered?

Cardiovascular drugs are meant to deal with disorders of the heart. The field includes diagnosis and treatment of congenital heart defects, coronary artery diseases, heart failure and other types of heart diseases. Cardiovascular diseases are diseases that affect the heart or blood vessels.

Pfizer's key cardiovascular drugs include Lipitor, Norvasc, BeneFIX, Refacto and Chantix.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Astra Zeneca, Merck, Schering-Plough, Bristol-Myers Squibb, Sanofi-Aventis, Glaxo SmithKline, Ranbaxy and Teva.

What buyers care about?

  1. Price of drugs
  2. Subsidies available in the form of reimbursements
  3. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Cardiovascular Drugs Revenue

This includes revenue from Pfizer’s drugs within the cardiovascular therapeutic class. More specifically, this is a sum of revenues from Lipitor, Norvasc, Chantix / Champix, BeneFIX, Revatio, Cardura, Fragmin, Refacto / Xyntha and Tikosyn. In addition, we also include probability-adjusted future revenues from cardiovascular drugs in Pfizer's phase 3 pipeline.

Pfizer's Cardiovascular Drugs Revenue has declined sharply over the last few years amounting to $5.55 billion in 2017.

Chart: Pfizer's Cardiovascular Drugs Revenue

Musculoskeletal Drugs

What is being offered?

Musculoskeletal system is also known as the Locomotor system. It is an organ system that provides animals and human beings the ability to move. It consists of body’s bones, muscles, cartilage, tendons, ligaments, joints and other connective tissues.

Pfizer competes in this segment with some well known brandssuch as Medrol, Celebrex and Enbrel.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Astra Zeneca, Merck, Schering-Plough, Bristol-Myers Squibb, Sanofi-Aventis, Glaxo SmithKline, Ranbaxy, Teva and others.

What buyers care about?

  1. Price of drugs
  2. Subsidies available in the form of reimbursements
  3. Availability of drugs

Strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Musculoskeletal Drugs Revenue

This includes revenue from Pfizer’s drugs within the musculoskeletal (relating musculature, skeleton and their joints) therapeutic class. More specifically, this is a sum of revenues from Enbrel (Outside U.S. & Canada), Celebrex, Xeljanz, Medrol, BMP2 and Toviaz. In addition, we also include probability-adjusted future revenues from musculoskeletal drugs in Pfizer's phase 3 pipeline.

Pfizer's Musculoskeletal Drugs Revenue increased until 2014, and dropped sharply in 2015 primarily due to both EU and US patents expiring for Celebrex as well as EU patent loss for Enbrel. In 2017, the figure stood at $5.6 billion.

Chart: Pfizer's Musculoskeletal Drugs Revenue

Neuroscience Drugs

What is being offered?

Neuroscience drugs are aimed at treating ailments related to the Central Nervous System, which is part of the nervous system that integrates the information it receives and coordinates the activity for all parts of the body of bilaterian animals, including human beings. It consists of the majority of the nervous system and consists of the brain and spinal cord. Of the entire central nervous system drugs market, antidepressants, anti-psychotics and anti-epileptics are the largest segments.

Following Wyeth's acquisition, Pfizer has become a dominant force in this segment with drugs such as Lyrica, Effexor, Zoloft and Neurontin.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Eli Lilly, Novartis, Astra Zeneca, Johnson & Johnson, Glaxo SmithKline, Forest Laboratories and Abbott Labs.

What buyers care about?

  1. Price of drugs
  2. Subsidies available in the form of reimbursements
  3. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Neuroscience Drugs Revenue

This includes revenue from Pfizer’s drugs within the neuroscience (relating to central nervous system) therapeutic class. More specifically, this is a sum of revenues from Lyrica, Effexor, Zoloft, Pristiq, Neurontin, Xanax/Xanax XR and Relpax. In addition, we also include probability-adjusted future revenues from neuroscience drugs in Pfizer's phase 3 pipeline.

Pfizer's Neuroscience Drugs Revenue increased from $4.94 billion in 2009 to nearly $7.52 billion in 2014 mainly due to growth in Lyrica. However, the figure declined in subsequent years amounting to $6.4 billion in 2017 as Lyrica lost its EU patent and Pfizer's business was hampered by adverse currency movements.

Chart: Pfizer's Neuroscience Drugs Revenue

Immunology Drugs

What is being offered?

Immuno-modulators are substances that alter the immune response by augmenting or reducing the ability of the immune system to produce antibodies. Some immuno-modulators are naturally present in the body and some of these are available in pharmacologic preparations. Pfizer has a small presence in this market with drugs such as Premarin, EpiPen & Rapamune.

Who is buying?

Chain stores (Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Novartis, Glaxo SmithKline, Astra-Zeneca, Takeda, 3M Pharmaceuticals and Merck.

What buyers care about?

  1. Price of drugs
  2. Subsidies available in the form of reimbursements
  3. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Immunology Drugs Revenue

This includes revenue from Pfizer’s drugs within the immunology therapeutic class. More specifically, this is a sum of revenues from Premarin Family, Rapamune and EpiPen. In addition, we also include probability-adjusted future revenues from immunology drugs in Pfizer's phase 3 pipeline.

Pfizer's Immunology Drugs Revenue was $270 million in 2009, which increased to nearly $1.42 billion by 2014 mainly due to the addition of Wyeth products such as Premarin and Rapamune. However, the figure fell in 2015 to $1.55 billion primarily due to loss of Rapamune's patent exclusivity, and decline in the sales of other drugs due to adverse currency effects. In 2017, Pfizer's Immunology Drugs Revenue stood at $1.27 billion.

Chart: Pfizer's Immunology Drugs Revenue

Alimentary & Metabolism Drugs

What is being offered?

Alimentary means pertaining to or caused by food or nutritive material. The alimentary canal is the portion of the digestive system consisting of the organs making up the route taken by food as it passes through the body from the mouth to the anus, including the esophagus, stomach and small & large intestines. Metabolism is the set of chemical reactions that happen in living organisms to sustain life.

Pfizer has a relatively small presence in this segment with drugs such as Viagra, Genotropin, Detrol, Depo-Provera and Somavert.

Who is buying?

Chain stores(Walgreens, CVS, Rite-Aid, Wal-Mart), clinics, long term care facilities, HMO, federal facilities, non-federal institutions and mail order pharmacies.

Competitors

Novo Nordisk, Merck, Eli Lilly, Novartis, Johnson & Johnson, Glaxo SmithKline and Abbott Labs

What buyers care about?

  1. Price of drugs
  2. Side effects
  3. Subsidies available in the form of reimbursements
  4. Availability of drugs

Pfizer strengths

  1. Creating novel drug delivery systems with emerging developers to enhance product value and efficacy
  2. Established presence in the market by virtue of big branded drugs
  3. Relentless focus on R&D
  4. Strong tie-ups with distribution channels

Pfizer's Alimentary/Metabolism Drugs Revenue

This includes revenue from Pfizer’s drugs within the alimentary & metabolism therapeutic class. More specifically, this is a sum of revenues from Viagra, Genotropin, Somavert and Depo-Provera. In addition, we also include probability-adjusted future revenues from alimentary and metabolism drugs in Pfizer's phase 3 pipeline.

Pfizer's Alimentary/Metabolism Drugs Revenue has declined over the past few years amounting to $1.95 billion in 2017. This can be attributed to lower Viagra sales post its patent loss in 2013.

Chart: Pfizer's Alimentary/Metabolism Drugs Revenue